Archives: Agenda

Paediatric trials bring amplified risks, tighter regulations, and higher stakes for patient safety – but the lessons learned extend far beyond children’s studies. In this case study, we examine the unique challenges of conducting a paediatric clinical trial and explore how its insights can be applied to improve planning, safety oversight, and operational efficiency in any therapeutic area.

• Navigating Complex Risk Profiles: Managing safety, dosing, and ethical considerations in vulnerable populations.
• Pharmacovigilance in Practice: Meeting rigorous monitoring and reporting demands under high scrutiny.
• Recruitment and Engagement Strategies: Overcoming barriers to participation with patients, caregivers, and advocacy groups.
• Transferable Takeaways: Applying lessons from paediatric research to accelerate and safeguard trials in all therapeutic areas.

Discover how artificial intelligence is transforming clinical research by streamlining processes from protocol design to regulatory submission. This session explores practical AI applications for overcoming recruitment challenges, ensuring ethical implementation, and shaping the future of oncology trials.

• Overcome Bottlenecks: Learn how AI breaks cycle inefficiencies in trial design and patient screening.
• Accelerate Recruitment: See how AI-driven models and molecular matching reduce screening time and failures.
• Implement Ethically: Understand frameworks for bias mitigation, data privacy, and regulatory compliance.
• Future Trends: Explore next-decade innovations like digital twins and foundation models.

• Analysing current market dynamics and funding trends shaping biotech growth in 2026
• Addressing ongoing talent shortages and evolving workforce strategies
• Funding and investment for biotechs in various regions of Europe: how has this shifted in 2026?
• The impact of national political and economic changes on the biotech landscape in Europe

Moderator: Kate Dokukina, Head of Clinical Trials, Eilean Therapeutics

• Understanding the UK’s new national start-up target and what it requires from sponsors and sites
• Ambitious FPI benchmarks: 30 days for rare disease trials and 60 days for other studies
• How the UK approach compares with clinical trial start-up timelines across European markets
• What sponsors and sites across Europe can learn from the UK’s drive to accelerate study activation
• Key enablers for faster start-up globally: streamlined processes, site capacity, and performance management

• Reimagining responsibilities across clinical trial functions in an AI- and automation-driven environment
• Evolving from task-based roles to strategic, insight-driven contributors across operations and data functions
• Redefining entry-level roles as technology reshapes foundational skills, expectations, and career pathways
• Identifying the new capabilities required to ensure technology enhances, not replaces the expertise of clinical trial professionals